Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Physiomics ( (GB:PYC) ).
Physiomics plc, a UK-based specialist in mathematical modelling, data science and biostatistics for drug development and personalised medicine, provides computational tools and bespoke models to help biotech and pharma companies de-risk decisions across discovery, pre-clinical and clinical stages. Its Virtual Tumour technology and multidisciplinary expertise have underpinned more than 140 commercial projects, serving blue-chip clients including Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics and Cancer Research UK.
The company has appointed transformation expert Stewart Williams as a consultant to support its board and management during a senior leadership transition, drawing on his more than 30 years of experience in complex programmes at organisations such as AstraZeneca, Victrex, BAE Systems and Co-operative Financial Services. Management expects Williams’ governance and operational delivery skills to bolster execution of Physiomics’ growth strategy, as the firm reports steady commercial activity from new and existing clients, reinforcing its push toward long-term, recurring engagements and operational strengthening during a pivotal phase of its development.
Spark’s Take on PYC Stock
According to Spark, TipRanks’ AI Analyst, PYC is a Neutral.
The score is held back primarily by weak financial performance: continued losses and persistent cash burn outweigh the benefit of a low-debt balance sheet and a 2025 revenue rebound. Technicals are moderately supportive with the price above major moving averages and a positive MACD, but elevated RSI suggests momentum may be stretched. Valuation is neutral-to-weak due to negative earnings and no dividend support.
To see Spark’s full report on PYC stock, click here.
More about Physiomics
Physiomics plc is a UK-based mathematical modelling, data science and biostatistics specialist focused on model-informed drug development and personalised medicine. The company supports biotech and pharma clients by integrating modelling and simulation, biostatistics, data science and bioinformatics to optimise discovery, pre-clinical and clinical programmes. Its offerings include bespoke computational models and its proprietary Virtual Tumour technology, and it has contributed to more than 140 commercial projects for clients such as Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics and Cancer Research UK.
The business targets the global life sciences sector, helping drug developers de-risk decision making and streamline development timelines through quantitative, data-driven insight. By building long-term, recurring client relationships, Physiomics positions itself as a specialised partner in complex, regulated environments, supporting the growing demand for advanced analytics and in silico modelling in therapeutic development.
Average Trading Volume: 7,001,323
Technical Sentiment Signal: Hold
Current Market Cap: £2.49M
Find detailed analytics on PYC stock on TipRanks’ Stock Analysis page.